EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A change in the timing for starting systemic therapies for hepatocellular carcinoma : the comparison of sorafenib and lenvatinib as the first-line treatment

T Hatanaka, S Kakizaki, T Nagashima, T Ueno, M Namikawa, H Tojima, D Takizawa, A Naganuma, H Arai, K Sato, N Harimoto, K Shirabe, T Uraoka

Acta Gastro Enterologica Belgica · 2021

DOI: 10.51821/84.1.109 ↗
AbstractBibliografische Angaben

Abstract

Aim : The aim of this retrospective multicenter study was to evaluate the differences in the timing for starting systemic therapies as the first-line treatment for hepatocellular carcinoma (HCC). Methods : A total of 375 patients with HCC treated with sorafenib from May 2009 to March 2018 and 56 patients treated with lenvatinib from March 2018 to November 2018 at our affiliated hospitals were included in this study. Results : The median ages of the sorafenib and lenvatinib groups were 71.0 (interquartile range [IQR] : 64.0-77.0) and 73.5 (IQR : 68.0 -80.0) years old, and 300 (80.0%) and 42 (75.0%) patients were men, respectively. The Barcelona Clinic Liver Cancer stage was early, intermediate and advanced in 39 patients (10.4%), 133 patients (35.5%) and 203 patients (54.1%) in the sorafenib group and 1 patient (1.8%), 17 patients (30.4%) and 38 patients (67.9%)in the lenvatinib group, respectively. In the analysis of intermediate HCC, patients who satisfied the criteria of TACE failure/refractoriness(P=0.017), those with ALBI grade 1 (P=0.040), and those with a serum AFP level

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →